These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32809875)

  • 21. [New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?].
    Juillière Y; Ferrières J
    Ann Cardiol Angeiol (Paris); 2016 Sep; 65(4):237-9. PubMed ID: 27242321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
    Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
    J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
    Nadruz W; Claggett BL; McMurray JJ; Packer M; Zile MR; Rouleau JL; Desai AS; Swedberg K; Lefkowitz M; Shi VC; Prescott MF; Solomon SD
    Circulation; 2016 Nov; 134(22):1785-1787. PubMed ID: 27895026
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
    Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
    Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
    de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
    Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
    Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
    Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
    JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports.
    Tschöpe C; Alogna A; Spillmann F; Faragli A; Schmidt G; Blaschke F; Kühl U; Hertel E; Willner M; Morris D; Post H; Noutsias M; Pieske B; Krackhardt F
    BMC Cardiovasc Disord; 2018 Jul; 18(1):155. PubMed ID: 30064356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
    Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
    Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
    Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices.
    Schnettler JK; Roehrich L; Just IA; Pergantis P; Stein J; Mueller M; Mulzer J; Knierim J; Falk V; Potapov FE; Schoenrath F
    J Card Fail; 2021 Dec; 27(12):1328-1336. PubMed ID: 34157393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits.
    Nayor M; Short MI; Rasheed H; Lin H; Jonasson C; Yang Q; Hveem K; Felix JF; Morrison AC; Wild PS; Morley MP; Cappola TP; Benson MD; ; ; Ngo D; Sinha S; Keyes MJ; Shen D; Wang TJ; Larson MG; Brumpton BM; Gerszten RE; Omland T; Vasan RS
    Circ Heart Fail; 2020 May; 13(5):e006749. PubMed ID: 32408813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
    Hoes MF; Tromp J; Ouwerkerk W; Bomer N; Oberdorf-Maass SU; Samani NJ; Ng LL; Lang CC; van der Harst P; Hillege H; Anker SD; Metra M; van Veldhuisen DJ; Voors AA; van der Meer P
    Eur J Heart Fail; 2020 Nov; 22(11):2102-2111. PubMed ID: 31797504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists.
    Dalal J; Chandra P; Ray S; Hazra PK; Hiremath J; Kumar V; Shah MK; Abdullakutty J; Ghosh D; Vasudevan K; Sahoo P
    Cardiol Ther; 2023 Sep; 12(3):445-471. PubMed ID: 37382802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.